Technical Analysis for IFRX - InflaRx N.V.

Grade Last Price % Change Price Change
F 3.79 -5.96% -0.24
IFRX closed down 5.96 percent on Thursday, March 4, 2021, on 1.53 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical IFRX trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Stochastic Buy Signal Bullish -5.96%
Wide Bands Range Expansion -5.96%
Oversold Stochastic Weakness -5.96%
180 Bearish Setup Bearish Swing Setup -11.66%
Calm After Storm Range Contraction -11.66%
Lower Bollinger Band Walk Weakness -11.66%
Wide Bands Range Expansion -11.66%
Oversold Stochastic Weakness -11.66%
Calm After Storm Range Contraction -12.06%
Older End-of-Day Signals for IFRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
1.5x Volume Pace about 7 hours ago
Down 5% about 7 hours ago
Down 3% about 7 hours ago
Down 2 % about 7 hours ago
Down 1% about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


InflaRx N.V. Description

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Development Immunology Immune System Antibodies Autoimmune Diseases Monoclonal Antibodies Monoclonal Antibody Autoimmune Disease Inflammatory Disease Inflammatory Diseases Complement System C5a Hidradenitis Suppurativa Vasculitis

Is IFRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.6979
52 Week Low 2.52
Average Volume 390,675
200-Day Moving Average 5.10
50-Day Moving Average 5.42
20-Day Moving Average 5.26
10-Day Moving Average 4.69
Average True Range 0.38
ADX 26.21
+DI 14.58
-DI 40.92
Chandelier Exit (Long, 3 ATRs ) 5.22
Chandelier Exit (Short, 3 ATRs ) 4.91
Upper Bollinger Band 6.79
Lower Bollinger Band 3.74
Percent B (%b) 0.02
BandWidth 57.98
MACD Line -0.41
MACD Signal Line -0.20
MACD Histogram -0.2098
Fundamentals Value
Market Cap 106.99 Million
Num Shares 28.2 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -1.82
Price-to-Sales 0.00
Price-to-Book 1.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.33
Resistance 3 (R3) 4.38 4.25 4.24
Resistance 2 (R2) 4.25 4.11 4.23 4.21
Resistance 1 (R1) 4.02 4.03 3.96 3.97 4.18
Pivot Point 3.89 3.89 3.86 3.87 3.89
Support 1 (S1) 3.66 3.75 3.60 3.61 3.40
Support 2 (S2) 3.53 3.67 3.51 3.37
Support 3 (S3) 3.30 3.53 3.34
Support 4 (S4) 3.25